found that intratumoral injection of the STING agonist can slow melanoma growth, improve vascular normalization, and promote the formation of TLS within the tumor microenvironment, thereby enhancing the anti‐tumor immune response.[47] In future studies, the relationship between the formation of TLS and the efficacy of immunotherapy in AFPGC patients with liver metastasis warrants further exploration. The gene discussed is STING1; the disease is melanoma.